VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 75 filers reported holding VIRIDIAN THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,287,421 | -35.5% | 3,082,622 | 0.0% | 4.98% | -57.6% |
| Q2 2023 | $73,335,577 | +6.8% | 3,082,622 | +14.2% | 11.73% | -12.6% |
| Q1 2023 | $68,684,566 | -12.9% | 2,699,865 | 0.0% | 13.41% | +0.9% |
| Q4 2022 | $78,863,057 | +80.5% | 2,699,865 | +26.7% | 13.28% | +97.0% |
| Q3 2022 | $43,693,000 | +103.8% | 2,130,308 | +15.0% | 6.74% | +59.7% |
| Q2 2022 | $21,438,000 | -37.4% | 1,852,919 | 0.0% | 4.22% | -23.9% |
| Q1 2022 | $34,260,000 | -6.5% | 1,852,919 | 0.0% | 5.55% | +10.8% |
| Q4 2021 | $36,632,000 | +11311.8% | 1,852,919 | +9404.6% | 5.01% | +12114.6% |
| Q3 2021 | $321,000 | -10.1% | 19,495 | 0.0% | 0.04% | -4.7% |
| Q2 2021 | $357,000 | +9.5% | 19,495 | 0.0% | 0.04% | +22.9% |
| Q1 2021 | $326,000 | +1.6% | 19,495 | 0.0% | 0.04% | -25.5% |
| Q4 2020 | $321,000 | – | 19,495 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $78,863,057 | 13.28% |
| COMMODORE CAPITAL LP | 2,020,166 | $59,009 | 8.89% |
| ACUTA CAPITAL PARTNERS, LLC | 396,500 | $11,581,765 | 7.13% |
| Fairmount Funds Management LLC | 1,369,623 | $40,006,688 | 6.35% |
| Paradigm Biocapital Advisors LP | 1,751,167 | $51,151,588 | 6.00% |
| Vivo Capital, LLC | 1,678,207 | $49,020 | 5.64% |
| TCG Crossover Management, LLC | 983,610 | $28,731,248 | 5.07% |
| Kynam Capital Management, LP | 1,034,697 | $30,223,499 | 4.64% |
| Octagon Capital Advisors LP | 824,200 | $24,074,882 | 3.75% |
| Logos Global Management LP | 1,000,000 | $29,210,000 | 3.42% |